FDA Approved Ebola Vaccine?

Posted by on September 6, 2023 3:04 am
Tags:
Categories: NATIONAL HEADLINES

The U.S. Food and Drug Administration (FDA) on August 3, 2023, approved Merck’s ERVEBO Zaire ebolavirus vaccine for individuals 12 months of age and older.

The vaccine was previously approved for individuals 18 years of age and older.

Merck announced:

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The vaccine was previously approved for use in individuals 18 years of age and older. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus and the duration of protection conferred by ERVEBO is unknown. The effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown. ERVEBO includes a contraindication for individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including rice protein.

“Ebola virus disease is contagious and potentially deadly in both children and adults. We’re proud of the approval of ERVEBO for the prevention of disease caused by Zaire ebolavirus in children as young as 12 months old, which is another milestone in our continued commitment to help address the global health threat caused by Zaire ebolavirus,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.

Separately, on July 20, 2023, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the expanded approval of ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live], for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus. ERVEBO is currently authorized for use in the European Union (EU) for individuals 18 years of age and older. The CHMP opinion will now be considered by the European Commission for amending the marketing authorization, and a final decision is expected in the third quarter of 2023.

The timing will raise suspicions considering the Ebola rumors at Burning Man.

Although rumors circulated that Ebola caused quarantines at the “festival,” the claims currently have no validity.

 

Read a full fact-check HERE.

FACT-CHECK: Quarantine At “Burning Man” Because Of Ebola?

However, we should still keep our antennas raised for suspicious Big Pharma activities.

Moderna, one of the mRNA COVID-19 shot manufacturers, wants to utilize mRNA technology for an Ebola shot.

Per Reuters in 2022:

Moderna Inc (MRNA.O) is nearing a deal with the U.S. government to develop vaccines against a range of biological threats including Ebola, Bloomberg News reported on Wednesday, citing people familiar with the matter.

The potential deal with the U.S. Department of Defense (DoD) would see Moderna’s mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease’s outbreak in Uganda, the report said.

Uganda declared the Ebola outbreak in September, and the disease has claimed 30 lives so far with the number of confirmed cases rising to 109.

Moderna’s shot would also target the more common Zaire strain of Ebola and the related Marburg virus, the report added.

The drugmaker declined to comment about any potential contract, but said it “continued to explore potential Ebola vaccines” and that it currently has a preclinical program for Ebola.

The U.S. government eventually finalized a $25 million deal to “design, manufacture and test mRNA vaccines for Ebola.”

UTMB Health wrote:

Scientists at the University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola. UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines. The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of COVID-19 vaccines early in the pandemic. Many international and regional news organizations also reported this story.

< E-Militia News home